To determine whether the amelioration of hepatic lipid deposition by Cori treatment via autophagy activation, we next examined the protein expression levels of LC3 and p62 in our established model of NAFLD in vitro. This evidence concerns the gene SQSTM1 and metabolic dysfunction-associated steatotic liver disease.